Roche Launches New Elevidys Trial After European Regulators Reject Duchenne Gene Therapy

Roche is launching a new clinical trial for its Duchenne muscular dystrophy gene therapy, Elevidys, in a direct response to European regulators who rejected the drug last year. The Swiss pharmaceutical giant announced the move after the European Medicines Agency delivered a negative review, stating the therapy failed to demonstrate long-term benefits for patients with the degenerative muscle condition. This new trial is a critical attempt to salvage the drug's prospects in Europe and other global markets where Roche holds commercial rights.

The planned Phase 3 study aims to generate the robust evidence regulators demanded. It will evaluate the safety and efficacy of Elevidys against a placebo over 72 weeks in approximately 100 boys in the early stages of Duchenne. Success in this trial is essential for Roche to resubmit the therapy for approval in Europe and file applications with other international regulatory agencies. The drug's developer, Sarepta Therapeutics, markets Elevidys in the U.S., but Roche's future with the product hinges on this new data.

This development underscores the high stakes and persistent controversy surrounding gene therapies for rare diseases. The need for another large trial signals the significant evidence gap identified by European officials and places immense pressure on Roche to deliver clear, long-term results. The outcome will not only determine the therapy's commercial future outside the U.S. but also influence the regulatory landscape for similar advanced treatments seeking global approval.